Barclays PLC Erasca, Inc. Transaction History

Barclays PLC

$357 Billion
Q4 2024

A detailed history of Barclays PLC transactions in Erasca, Inc. stock. As of the latest transaction made, Barclays PLC holds 377,764 shares of ERAS stock, worth $483,537. This represents 0.0% of its overall portfolio holdings.

Number of Shares

377,764

Previous 343,930 9.84%

Holding current value

$483,537

Previous $939,000 0.96%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$2.44 - $3.23 $82,554 - $109,283	33,834 Added 9.84%	377,764 $948,000
Q3 2024 Nov 15, 2024	BUY	$2.17 - $3.28 $643,745 - $973,034	296,657 Added 627.54%	343,930 $939,000
Q2 2024 Aug 14, 2024	SELL	$1.79 - $2.63 $30,512 - $44,830	-17,046 Reduced 26.5%	47,273 $111,000
Q1 2024 May 15, 2024	SELL	$1.67 - $2.55 $115,846 - $176,890	-69,369 Reduced 51.89%	64,319 $132,000
Q4 2023 Feb 15, 2024	BUY	$1.67 - $2.49 $151,569 - $225,992	90,760 Added 211.42%	133,688 $284,000
Q3 2023 Nov 07, 2023	BUY	$1.97 - $2.91 $10,403 - $15,367	5,281 Added 14.03%	42,928 $85,000
Q2 2023 Aug 03, 2023	SELL	$2.57 - $3.3 $46,134 - $59,238	-17,951 Reduced 32.29%	37,647 $103,000
Q1 2023 May 04, 2023	SELL	$2.74 - $4.44 $285,406 - $462,483	-104,163 Reduced 65.2%	55,598 $168,000
Q4 2022 Feb 13, 2023	BUY	$3.89 - $8.57 $399,397 - $879,907	102,673 Added 179.85%	159,761 $688,000
Q3 2022 Nov 03, 2022	BUY	$5.82 - $10.68 $297,367 - $545,683	51,094 Added 852.42%	57,088 $445,000
Q2 2022 Aug 12, 2022	SELL	$4.58 - $8.72 $34,936 - $66,516	-7,628 Reduced 56.0%	5,994 $33,000
Q1 2022 May 16, 2022	BUY	$8.6 - $15.48 $117,149 - $210,868	13,622 New	13,622 $117,000

Others Institutions Holding ERAS

# of Institutions

153

Shares Held

227M

Call Options Held

10.9K

Put Options Held

65.1K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $156M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account